1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Translational Accelerator: AV-CTIP Device Innovation Award is sponsored by Additional Ventures. The Translational Accelerator: AV-CTIP Device Innovation Award is a grant from Additional Ventures, in partnership with the Consortium for Technology and Innovation in Pediatrics (CTIP), that funds early-stage medical device innovation purpose-built for patients with single vent…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Translational Accelerator: AV-CTIP Device Innovation Award – Additional Ventures Translational Accelerator: AV-CTIP Device Innovation Award Translational research in rare and complex conditions often stalls between promising concepts and patient-ready solutions. The Additional Ventures Translational Accelerator was developed to help researchers overcome the “valley of death” in single ventricle translational research.
By removing early stage roadblocks and equipping researchers with both funding and strategic expertise, the Accelerator helps translate high-potential discoveries to clinical realities. The Accelerator supports two independent award streams that each target a critical area of need in translational science: therapeutics and devices.
The AV-CTIP Device Innovation Award underscores our commitment to tackling device innovation as a critical frontier in single ventricle care. The AV-CTIP Device Innovation Award Medical devices play a vital role in single ventricle care, but virtually no medical devices are specifically designed or engineered to meet the needs of single ventricle patients.
To close this gap, Additional Ventures (AV), in partnership with the Consortium for Technology & Innovation in Pediatrics (CTIP) , is launching the AV-CTIP Device Innovation Award . This initiative advances early-stage device concepts purpose-built for single ventricle patients across every stage of treatment.
By supporting early-stage device innovators, this program seeks to fill critical gaps in care for single ventricle patients, catalyze clinical translation, and ultimately improve long term outcomes for this high-need community.
This award combines Additional Ventures’ commitment to revolutionizing treatment and care for individuals with single ventricle heart disease with CTIP’s expertise in medical device development and commercialization. Together, we are providing the financial support, technical resources, and disease-specific expertise innovators need to move high-potential technologies from concept toward clinical impact.
Awardees will be eligible for: Up to $1M in milestone-driven funding , up to approximately 3 years in total, with access to advising, services, and support throughout the award term. Tailored technical and business support through CTIP — including expert coaching, strategic connections, and access to consulting and service providers.
Supplemental resources to advance projects through critical phases of device development, from early prototyping to clinical readiness. While surgical intervention has improved survival in single ventricle heart disease, patients still experience progressive complications. Few medical or device-based innovations address the unique physiological challenges or downstream complications of single ventricle heart disease.
We are particularly interested in technologies that can: Improve or augment the Fontan physiology , including support for low-pressure pulmonary flow, single-ventricle function, or optimized conduit/shunt performance Enable earlier intervention in failing Fontan patients or improve candidacy for transplantation Prevent, monitor, or treat sequelae such as lymphatic congestion, liver fibrosis, arrhythmias, or protein-losing enteropathy Support quality of life and daily function across pediatric and adult populations Deliver diagnostic or monitoring capabilities that provide actionable insights into Fontan performance and end-organ health Teams affiliated with U.S.-based academic institutions and companies are invited to apply.
At minimum, teams must include a coordinating project lead, project manager, and appropriate clinical and technical expertise to support the success of their asset. Applicants are welcome to include additional key personnel critical to the success of the project.
These may include, but are not limited to: Clinical or technical collaborators Regulatory, reimbursement, or commercialization experts Consultants or contracted specialists in relevant areas (e.g., human factors, design controls, biostatistics) All additional personnel should have a clearly defined role and level of effort. Letters of support or biosketches may be requested to document and assess their involvement.
Up to $1M in milestone-driven funding , up to approximately 3 years in total, with access to advising, services, and support throughout the award term. Full proposal invitation: Applicants are encouraged to consult with program staff prior to submitting an LOI. Questions regarding scientific fit can be directed to Additional Ventures: grants@additionalventures.
org . All other inquiries can be directed to CTIP: info@ctipmedtech. org .
Applicants may also bring questions to live information sessions with program staff, scheduled for September 24 and October 24 , 2025, 10-11am PST, and hosted on Zoom. To apply, view the full Request for Proposals and applications guidelines on the CTIP site.
According to the current listing, eligibility includes: U. S. -based academic institutions and companies. Teams must include a coordinating project lead, project manager, and appropriate clinical and technical expertise. Confirm the full requirements in the official notice before applying.
Translational Accelerator: AV-CTIP Device Innovation Award is funded by Additional Ventures. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleAt CGI on September 23, 2026, Global Impact Ventures committed $100 million over three years across economic opportunity, health, education, climate resilience and humanitarian needs. There is no application portal. The access route is the intermediary infrastructure — fiscal sponsorship, grantmaking administration, and a 250-organization network.
Read articleThe RFI closed June 22. Now the forum is standing up. AI Forge is a jointly governed, university-led venture funding interpretability, control, and adversarial robustness in one-year Project Ventures — here's how the 15 challenges, the CAISI tie, and the nonprofit administrator reshape who gets funded.
Read article